Loading…
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $-83M | $-117M | $-79M | -228.0% | 181.5% | - |
| 2024 | $2M | $-88M | $-84M | $-78M | -52.1% | - | - |
| 2023 | $0M | $-81M | $-81M | $-75M | -47.8% | - | - |
| 2022 | $0M | $-56M | $-58M | $-59M | 58.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 2.27 | 6.39 |
| Operating Expense | 59 | 84.53 | 94.18 | 93.73 |
| Operating Income | -59 | -84.53 | -91.91 | -87.34 |
| EBITDA | -56.49 | -80.90 | -88.34 | -83.06 |
| EBIT | -59 | -84.53 | -91.91 | -87.34 |
| Pretax Income | -58.02 | -81.14 | -83.44 | -116.62 |
| Tax Provision | 0.01 | 0.03 | 0.14 | 0.64 |
| Net Income | -58.03 | -81.17 | -83.58 | -117.26 |
| Net Income Common Stockholders | -58.03 | -81.17 | -83.58 | -117.26 |
| Total Expenses | 59 | 84.53 | 94.18 | 93.73 |
| Interest Expense | 0.12 | 0 | 0 | 0 |
| Interest Income | 0.95 | 0 | 0 | 0 |
| Research And Development | 42.20 | 57.25 | 63.64 | 65.58 |
| Selling General And Administration | 16.80 | 27.28 | 30.55 | 28.16 |
| Normalized EBITDA | -56.49 | -80.90 | -88.34 | -48.55 |
| Normalized Income | -58.03 | -81.17 | -83.58 | -89.99 |
| Basic EPS | -7.25 | -53.08 | -9.37 | 0 |
| Diluted EPS | -7.25 | -53.08 | -9.37 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | -7.25 |
| Tax Rate For Calcs | 0.21 | 0 | 0.21 | 0.21 |
| Total Unusual Items | 0 | 0 | 0 | -34.51 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | -34.51 |
| Net Income From Continuing Operation Net Minority Interest | -58.03 | -81.17 | -83.58 | -117.26 |
| Reconciled Depreciation | 2.51 | 3.63 | 3.56 | 4.28 |
| Net Interest Income | 0.83 | 0 | 0 | 0 |
| Net Income From Continuing And Discontinued Operation | -58.03 | -81.17 | -83.58 | -117.26 |
| Total Operating Income As Reported | -59 | -84.53 | -91.91 | -121.86 |
| Diluted Average Shares | 8 | 1.53 | 8.92 | 0 |
| Basic Average Shares | 8 | 1.53 | 8.92 | 0 |
| Diluted NI Availto Com Stockholders | -58.03 | -81.17 | -83.58 | -117.26 |
| Net Income Including Noncontrolling Interests | -58.03 | -81.17 | -83.58 | -117.26 |
| Net Income Continuous Operations | -58.03 | -81.17 | -83.58 | -117.26 |
| Other Income Expense | 0.98 | 3.39 | 8.47 | -29.28 |
| Other Non Operating Income Expenses | 0.98 | 3.39 | 8.47 | 5.23 |
| Special Income Charges | 0 | 0 | 0 | -34.51 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 30.89 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 3.63 |
| Net Non Operating Interest Income Expense | 0.83 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0.12 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.95 | 0 | 0 | 0 |
| General And Administrative Expense | 16.80 | 27.28 | 30.55 | 28.16 |
| Other Gand A | 7.83 | 13.84 | 17.39 | 13.77 |
| Salaries And Wages | 8.97 | 13.44 | 13.16 | 14.39 |
| Operating Revenue | 0 | 0 | 2.27 | 6.39 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Korro Bio, Inc.this co. | KRRO | $182M | - | 2.31 | -228.0% | -1.81 |
| Cartesian Therapeutics, Inc. | RNAC | $190M | - | -1.33 | 103.2% | -0.70 |
| Quantum-Si incorporated | QSI | $187M | - | 0.85 | -46.0% | -0.31 |
| KORU Medical Systems, Inc. | KRMD | $185M | - | 10.79 | -15.5% | -78.39 |
| Humacyte, Inc. | HUMA | $182M | - |
| 51.25 |
| -1313.4% |
| -1.97 |
| CVRx, Inc. | CVRX | $181M | - | 4.60 | -135.6% | -3.08 |
| AirSculpt Technologies, Inc. | AIRS | $179M | - | 1.87 | -13.3% | 32.00 |
| Stereotaxis, Inc. | STXS | $177M | - | 12.91 | -115.6% | -9.48 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $176M | - | 0.65 | -50.6% | 0.32 |
| Peer Median | - | - | 3.23 | -48.3% | -1.34 | |